---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088572"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:27:37.665018+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical enters exclusive distribution deal for collagen dermal matrix with Regenity Biosciences

## Summary
- Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.
- AVITA to pay $2M upon 510(k) clearance, up to $3M more by Jan 4, 2026 contingent on clinical results.
- Revenue sharing: 50% of avg sales price first 2 years, then 60% in subsequent years.
- AVITA to commercialize under its brand in US, EU, Australia, Japan; clinical studies planned for 2025.
- CEO Jim Corbett says collaboration strengthens portfolio and may establish new standard of care.

## SEC filing metadata
- accession: 0000950170-24-088572
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024088572/0000950170-24-088572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024088572/rcel-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088572
- JSON: https://secwatch.observer/filing/0000950170-24-088572.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.